NCT04552769View on ClinicalTrials.gov

Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 10, 2020

Primary Completion Date

April 12, 2023

Study Completion Date

January 5, 2025

Conditions
Thyroid CancerAnaplastic Thyroid CancerUndifferentiated Thyroid Cancer
Interventions
DRUG

Abemaciclib

200 mg orally

Trial Locations (1)

94305

Stanford University, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT04552769 - Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer | Biotech Hunter | Biotech Hunter